Sei Naito

18PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsExercise physiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 17, 2026
A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study.

Shuzo Hamamoto, Masahiro Nozawa, Suguru Shirotake

|Nov 26, 2025
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.

Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake

|May 14, 2025
Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma.

Yuki Takai, Sei Naito, Hiromi Ito

|May 07, 2025
Association Between Overactive Bladder and Sarcopenia in Older Adults: A Population-Based Cohort Study.

Suguru Ito, Mayu Yagi, Kaori Sakurada

Pageof 3